PORTERs Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market
Semaglutide can address several aspects of metabolic syndrome, making it beneficial for these patients
They are intended to address specific gaps, such as meeting individual patient requirements or providing access during a verified drug shortage
As of 2026, retatrutide is still in phase 3 clinical trials under the TRIUMPH program
Using expired semaglutide has potential risks of unexpected side effects or other serious health problems
Among these are carcinomas of the pancreas, liver, colon, and prostate [13]